This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (a synthetic cannabinoid receptor agonist (synthetic cannabinoid) originally patented under the code name SGT-78)., carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.

Table of contents:
· Foreword
· EMCDDA actions on monitoring and responding to new drugs
· Europol–EMCDDA Joint Report on CUMYL-4CN-BINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) — a summary
· Risk Assessment Report on a new psychoactive substance: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA)
· Technical report on 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA)
· Participants of the risk assessment meeting, 7-8 November 2017